

Thai Nakin Hospital Public Company Limited  
and its subsidiary  
Review report interim financial information  
For the three-month and nine-month periods ended  
30 April 2023

## **Independent Auditor's Report on Review of Interim Financial Information**

To the Shareholders of Thai Nakarin Hospital Public Company Limited

I have reviewed the accompanying consolidated statement of financial position of Thai Nakarin Hospital Public Company Limited and its subsidiary ("the Group") as at 30 April 2023, and the related consolidated statements of comprehensive income for the three-month and nine-month period then ended, the related statements of changes in shareholders' equity and cash flows for the nine-month period then ended, as well as the condensed notes to the interim consolidated financial statements. I have also reviewed the separate financial information of Thai Nakarin Hospital Public Company Limited for the same period (collectively "interim financial information").

Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard 34 Interim Financial Reporting.

My responsibility is to express a conclusion on this interim financial information based on my review.

### **Scope of review**

I conducted my review in accordance with Thai Standard on Review Engagements 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Thai Standards on Auditing and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

### **Conclusion**

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard 34 Interim Financial Reporting.

Samran Taengcham

Certified Public Accountant (Thailand) No. 8021

EY Office Limited

Bangkok: 14 June 2023

Thai Nakarin Hospital Public Company Limited and its subsidiary

Statement of financial position

As at 30 April 2023

(Unit: Thousand Baht)

	Note	<u>Consolidated financial statements</u>		<u>Separate financial statements</u>	
		30 April 2023	31 July 2022	30 April 2023	31 July 2022
		(Unaudited but reviewed)	(Audited)	(Unaudited but reviewed)	(Audited)
<b>Assets</b>					
<b>Current assets</b>					
Cash and cash equivalents	3	1,130,378	699,568	1,128,543	697,019
Trade and other receivables	2, 4	216,208	360,768	216,027	360,588
Inventories		38,150	36,172	38,150	36,172
Other current financial assets	5	170,495	472,547	170,495	472,547
Other current assets		546	1,532	546	1,532
<b>Total current assets</b>		<b>1,555,777</b>	<b>1,570,587</b>	<b>1,553,761</b>	<b>1,567,858</b>
<b>Non-current assets</b>					
Investment in subsidiary	6	-	-	1,000	1,000
Property, plant and equipment	7	902,706	778,999	902,706	778,999
Intangible assets		4,271	3,374	4,271	3,374
Right-of-use assets	8	575,334	592,180	575,334	592,180
Deferred tax assets		27,650	24,446	27,650	24,446
Other non-current assets		146	99	146	99
<b>Total non-current assets</b>		<b>1,510,107</b>	<b>1,399,098</b>	<b>1,511,107</b>	<b>1,400,098</b>
<b>Total assets</b>		<b>3,065,884</b>	<b>2,969,685</b>	<b>3,064,868</b>	<b>2,967,956</b>

The accompanying notes are an integral part of the financial statements.

Thai Nakarin Hospital Public Company Limited and its subsidiary

Statement of financial position (continued)

As at 30 April 2023

(Unit: Thousand Baht)

	Note	Consolidated financial statements		Separate financial statements	
		30 April 2023 (Unaudited but reviewed)	31 July 2022 (Audited)	30 April 2023 (Unaudited but reviewed)	31 July 2022 (Audited)
<b>Liabilities and shareholders' equity</b>					
<b>Current liabilities</b>					
Trade and other payables	9	198,657	210,248	198,459	209,132
Doctor fee payable	2	96,969	106,572	96,969	106,572
Income tax payable		10,916	26,801	10,916	26,710
Other current liabilities		33,754	31,154	33,754	31,154
<b>Total current liabilities</b>		<b>340,296</b>	<b>374,775</b>	<b>340,098</b>	<b>373,568</b>
<b>Non-current liabilities</b>					
Provision for long-term employee benefits		107,007	102,956	107,007	102,956
Other non-current financial liabilities		3,550	7,954	3,550	7,954
<b>Total non-current liabilities</b>		<b>110,557</b>	<b>110,910</b>	<b>110,557</b>	<b>110,910</b>
<b>Total liabilities</b>		<b>450,853</b>	<b>485,685</b>	<b>450,655</b>	<b>484,478</b>
<b>Shareholders' equity</b>					
Share capital					
Registered					
180,000,000 ordinary shares of Baht 1 each		180,000	180,000	180,000	180,000
Issued and fully paid-up					
180,000,000 ordinary shares of Baht 1 each		180,000	180,000	180,000	180,000
Share premium		20,538	20,538	20,538	20,538
Retained earnings					
Appropriated - statutory reserve		18,000	18,000	18,000	18,000
Unappropriated		2,396,493	2,265,462	2,395,675	2,264,940
<b>Equity attributable to owners of the company</b>		<b>2,615,031</b>	<b>2,484,000</b>	<b>2,614,213</b>	<b>2,483,478</b>
<b>Total liabilities and shareholders' equity</b>		<b>3,065,884</b>	<b>2,969,685</b>	<b>3,064,868</b>	<b>2,967,956</b>

The accompanying notes are an integral part of the financial statements.

Directors

(Unaudited but reviewed)

**Thai Nakarin Hospital Public Company Limited and its subsidiary**

**Statement of comprehensive income**

**For the three-month period ended 30 April 2023**

(Unit: Thousand Baht except earnings per share expressed in Baht)

	<u>Consolidated financial statements</u>		<u>Separate financial statements</u>	
	30 April	30 April	30 April	30 April
Note	2023	2022	2023	2022
<b>Profit and loss:</b>				
<b>Revenues</b>				
Revenues from hospital operations	580,428	627,657	580,428	627,657
Other income	5,415	7,452	5,425	3,903
<b>Total revenues</b>	<b>585,843</b>	<b>635,109</b>	<b>585,853</b>	<b>631,560</b>
<b>Expenses</b>				
Cost of hospital operations and goods sold	429,695	443,202	429,695	440,304
Administrative expenses	62,124	52,566	62,086	52,545
<b>Total expenses</b>	<b>491,819</b>	<b>495,768</b>	<b>491,781</b>	<b>492,849</b>
<b>Operating profit</b>	<b>94,024</b>	<b>139,341</b>	<b>94,072</b>	<b>138,711</b>
Finance income	2,199	1,120	2,198	1,120
<b>Profit before income tax expenses</b>	<b>96,223</b>	<b>140,461</b>	<b>96,270</b>	<b>139,831</b>
Income tax expenses	10 (18,235)	(27,112)	(18,234)	(27,017)
<b>Profit for the period</b>	<b>77,988</b>	<b>113,349</b>	<b>78,036</b>	<b>112,814</b>
<b>Other comprehensive income:</b>				
<b>Other comprehensive income for the period</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total comprehensive income for the period</b>	<b>77,988</b>	<b>113,349</b>	<b>78,036</b>	<b>112,814</b>
<b>Basic earnings per share</b>				
Profit (Baht)	0.43	0.63	0.43	0.63
Weighted average number of ordinary shares (Thousand shares)	180,000	180,000	180,000	180,000

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

**Thai Nakarin Hospital Public Company Limited and its subsidiary**

**Statement of comprehensive income**

**For the nine-month period ended 30 April 2023**

(Unit: Thousand Baht except earnings per share expressed in Baht)

	<u>Consolidated financial statements</u>		<u>Separate financial statements</u>	
	30 April	30 April	30 April	30 April
Note	2023	2022	2023	2022
<b>Profit and loss:</b>				
<b>Revenues</b>				
Revenues from hospital operations	1,765,342	1,986,884	1,765,342	1,986,884
Other income	18,629	12,728	17,866	9,179
<b>Total revenues</b>	<b>1,783,971</b>	<b>1,999,612</b>	<b>1,783,208</b>	<b>1,996,063</b>
<b>Expenses</b>				
Cost of hospital operations and goods sold	1,305,689	1,367,942	1,305,343	1,365,044
Administrative expenses	189,361	171,907	189,246	171,886
<b>Total expenses</b>	<b>1,495,050</b>	<b>1,539,849</b>	<b>1,494,589</b>	<b>1,536,930</b>
<b>Operating profit</b>	<b>288,921</b>	<b>459,763</b>	<b>288,619</b>	<b>459,133</b>
Finance income	6,048	3,450	6,045	3,450
<b>Profit before income tax expenses</b>	<b>294,969</b>	<b>463,213</b>	<b>294,664</b>	<b>462,583</b>
Income tax expenses	10 (55,938)	(89,786)	(55,929)	(89,691)
<b>Profit for the period</b>	<b>239,031</b>	<b>373,427</b>	<b>238,735</b>	<b>372,892</b>
<b>Other comprehensive income:</b>				
<b>Other comprehensive income for the period</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total comprehensive income for the period</b>	<b>239,031</b>	<b>373,427</b>	<b>238,735</b>	<b>372,892</b>
<b>Basic earnings per share</b>				
Profit (Baht)	1.33	2.07	1.33	2.07
Weighted average number of ordinary shares				
(Thousand shares)	180,000	180,000	180,000	180,000

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

**Thai Nakarin Hospital Public Company Limited and its subsidiary**

**Statement of changes in shareholders' equity**

**For the nine-month period ended 30 April 2023**

(Unit: Thousand Baht)

	<b>Consolidated financial statements</b>				<b>Total shareholders' equity</b>
	<b>Issued and paid-up share capital</b>	<b>Share premium</b>	<b>Retained earnings Appropriated - statutory reserve</b>	<b>Unappropriated</b>	
<b>Balance as at 1 August 2021</b>	180,000	20,538	18,000	1,930,110	2,148,648
Total comprehensive income for the period	-	-	-	373,427	373,427
Dividend paid (Note 11)	-	-	-	(90,000)	(90,000)
<b>Balance as at 30 April 2022</b>	<u>180,000</u>	<u>20,538</u>	<u>18,000</u>	<u>2,213,537</u>	<u>2,432,075</u>
<b>Balance as at 1 August 2022</b>	180,000	20,538	18,000	2,265,462	2,484,000
Total comprehensive income for the period	-	-	-	239,031	239,031
Dividend paid (Note 11)	-	-	-	(108,000)	(108,000)
<b>Balance as at 30 April 2023</b>	<u>180,000</u>	<u>20,538</u>	<u>18,000</u>	<u>2,396,493</u>	<u>2,615,031</u>

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

**Thai Nakarin Hospital Public Company Limited and its subsidiary**

**Statement of changes in shareholders' equity**

**For the nine-month period ended 30 April 2023**

(Unit: Thousand Baht)

	<b>Separate financial statements</b>				<b>Total shareholders' equity</b>
	<b>Issued and paid-up share capital</b>	<b>Share premium</b>	<b>Retained earnings Appropriated - statutory reserve</b>	<b>Unappropriated</b>	
<b>Balance as at 1 August 2021</b>	180,000	20,538	18,000	1,930,110	2,148,648
Total comprehensive income for the period	-	-	-	372,892	372,892
Dividend paid (Note 11)	-	-	-	(90,000)	(90,000)
<b>Balance as at 30 April 2022</b>	<u>180,000</u>	<u>20,538</u>	<u>18,000</u>	<u>2,213,002</u>	<u>2,431,540</u>
<b>Balance as at 1 August 2022</b>	180,000	20,538	18,000	2,264,940	2,483,478
Total comprehensive income for the period	-	-	-	238,735	238,735
Dividend paid (Note 11)	-	-	-	(108,000)	(108,000)
<b>Balance as at 30 April 2023</b>	<u>180,000</u>	<u>20,538</u>	<u>18,000</u>	<u>2,395,675</u>	<u>2,614,213</u>

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

**Thai Nakarin Hospital Public Company Limited and its subsidiary**

**Statement of cash flows**

**For the nine-month period ended 30 April 2023**

(Unit: Thousand Baht)

	<u>Consolidated financial statements</u>		<u>Separate financial statements</u>	
	30 April	30 April	30 April	30 April
	<u>2023</u>	<u>2022</u>	<u>2023</u>	<u>2022</u>
<b>Cash flows from operating activities</b>				
Profit before tax	294,969	463,213	294,664	462,583
Adjustments to reconcile profit before tax to net cash provided by (paid from) operating activities:				
Depreciation and amortisation expenses	85,902	64,738	85,902	64,738
Allowance for expected credit losses	12,669	6,708	12,669	6,708
Long-term employee benefit expenses	10,442	10,319	10,442	10,319
(Gain) loss on disposals of equipment	(1,742)	564	(1,742)	564
Interest income	<u>(6,048)</u>	<u>(3,450)</u>	<u>(6,045)</u>	<u>(3,450)</u>
Profit from operating activities before changes in operating assets and liabilities	396,192	542,092	395,890	541,462
Decrease (increase) in operating assets				
Trade and other receivables	132,429	(141,052)	132,430	(141,081)
Inventories	(1,978)	(14,683)	(1,978)	(14,683)
Other current assets	986	10,176	986	10,176
Other non-current assets	(47)	102	(47)	102
Increase (decrease) in operating liabilities				
Trade and other payables	(8,212)	46,417	(7,294)	43,507
Doctor fee payable	(9,603)	26,940	(9,603)	26,940
Other current liabilities	2,600	(20,108)	2,600	(20,177)
Provision for long-term employee benefits	(6,391)	(4,129)	(6,391)	(4,129)
Other non-current financial liabilities	<u>(4,404)</u>	<u>-</u>	<u>(4,404)</u>	<u>-</u>
Cash from operating activities	501,572	445,755	502,189	442,117
Cash paid for income tax	<u>(75,027)</u>	<u>(102,002)</u>	<u>(74,927)</u>	<u>(102,002)</u>
<b>Net cash from operating activities</b>	<u>426,545</u>	<u>343,753</u>	<u>427,262</u>	<u>340,115</u>

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

**Thai Nakarin Hospital Public Company Limited and its subsidiary**

**Statement of cash flows (continued)**

**For the nine-month period ended 30 April 2023**

(Unit: Thousand Baht)

	<u>Consolidated financial statements</u>		<u>Separate financial statements</u>	
	30 April 2023	30 April 2022	30 April 2023	30 April 2022
<b>Cash flows from investing activities</b>				
Investment in subsidiary	-	-	-	(1,000)
Interest received	5,510	3,942	5,507	3,942
Decrease in other current financial assets	302,052	97,948	302,052	97,948
Cash paid for purchases of building improvement and equipment	(196,699)	(188,640)	(196,699)	(188,640)
Cash paid for purchase of intangible assets	(1,422)	-	(1,422)	-
Increase in right-of-use assets	-	(7,348)	-	(7,348)
Cash received from disposals of equipment	2,824	510	2,824	510
<b>Net cash from (used in) investing activities</b>	<b>112,265</b>	<b>(93,588)</b>	<b>112,262</b>	<b>(94,588)</b>
<b>Cash flows from financing activities</b>				
Dividend paid	(108,000)	(90,000)	(108,000)	(90,000)
<b>Net cash used in financing activities</b>	<b>(108,000)</b>	<b>(90,000)</b>	<b>(108,000)</b>	<b>(90,000)</b>
<b>Net increase in cash and cash equivalents</b>	<b>430,810</b>	<b>160,165</b>	<b>431,524</b>	<b>155,527</b>
Cash and cash equivalents at beginning of period	699,568	366,744	697,019	366,744
<b>Cash and cash equivalents at end of period (Note 3)</b>	<b>1,130,378</b>	<b>526,909</b>	<b>1,128,543</b>	<b>522,271</b>
<b>Supplemental cash flows information</b>				
Non-cash items				
Accounts payable - construction and equipment purchase	45,934	12,474	45,934	12,474

The accompanying notes are an integral part of the financial statements.

**Thai Nakarin Hospital Public Company Limited and its subsidiary**  
**Notes to consolidated interim financial statements**  
**For the three-month and nine-month periods ended 30 April 2023**

**1. General information**

**1.1 Corporate information**

Thai Nakarin Hospital Public Company Limited (“the Company”) is a public company incorporated and domiciled in Thailand. The Company is principally engaged in hospital business. The registered office of the Company is at No. 345 Thepparat Road, Kwaeng Bangna Nuea, Khet Bangna, Bangkok.

**1.2 Basis for the preparation of interim financial statements**

These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 Interim Financial Reporting, with the Company choosing to present condensed interim financial statements. However, the Company has presented the statements of financial position, comprehensive income, changes in shareholders’ equity, and cash flows in the same format as that used for the annual financial statements.

The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events and circumstances so as not to duplicate information previously reported. These interim financial statements should therefore be read in conjunction with the latest annual financial statements.

The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the Thai language financial statements.

**1.3 Basis of consolidation**

These interim consolidated financial statements include the financial statements of Thai Nakarin Hospital Public Company Limited and its subsidiary (“the Group”) and have been prepared on the same basis as that applied for the consolidated financial statements for the year ended 31 July 2022. There have been no changes in the structure of the subsidiary during the current period.

#### 1.4 Significant accounting policies

The interim financial statements are prepared using the same accounting policies and methods of computation as were used for the financial statements for the year ended 31 July 2022.

##### Financial reporting standards that became effective in the current year

The revised financial reporting standards which are effective for fiscal years beginning on or after 1 January 2022, do not have any significant impact on the Group's financial statements.

##### Financial reporting standards that will become effective for fiscal years beginning on or after 1 January 2023

The Federation of Accounting Professions issued a number of revised financial reporting standards and interpretations, which are effective for fiscal years beginning on or after 1 January 2023. The management of the Group is currently evaluating the impact of these standards to the financial statements in the years when they are adopted.

#### 2. Related party transactions

During the periods, the Company had significant business transactions with related parties. Such transactions, which are summarised below, arose in the ordinary course of business and were concluded on commercial terms and bases agreed upon between the Company and those related parties.

	<u>Transfer pricing policy</u>
Revenue from hospital operations	Based on the price charged to normal customers
Rental income	Rates as stipulated in the agreements
Purchase fixed assets	Rates as stipulated in the agreements
Doctor fee expenses (directors and management)	Paid at the same rate as other doctors in the hospital
Medical welfare	Under the Company's regulations, medical welfare benefits are granted to directors, their spouses, children and parents, up to a specified amount per annum. These benefits exclude doctor fees, examinations conducted on other premises and special equipment charges

(Unaudited but reviewed)

(Unit: Thousand Baht)

For three-month periods ended 30 April

	Consolidated		Separate	
	financial statements		financial statements	
	<u>2023</u>	<u>2022</u>	<u>2023</u>	<u>2022</u>
<b><u>Transactions with related companies and persons</u></b>				
Revenue from hospital operations	-	8,960	-	8,960
Purchase fixed assets	16,100	-	16,100	-
Doctor fee expenses (directors and management)	2,869	3,777	2,869	3,777
Medical welfare	1,094	921	1,094	921

(Unit: Thousand Baht)

For nine-month periods ended 30 April

	Consolidated		Separate	
	financial statements		financial statements	
	<u>2023</u>	<u>2022</u>	<u>2023</u>	<u>2022</u>
<b><u>Transactions with related companies and persons</u></b>				
Revenue from hospital operations	55	16,055	55	16,055
Purchase fixed assets	16,100	-	16,100	-
Doctor fee expenses (directors and management)	7,763	12,037	7,763	12,037
Medical welfare	3,432	2,824	3,432	2,824

The balances of accounts as at 30 April 2023 and 31 July 2022 between the Company and its related parties are as follows:

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	30 April 2023	31 July 2022	30 April 2023	31 July 2022
<b><u>Trade receivables - related parties</u></b>				
<b>(Note 4)</b>				
Related companies (related by common shareholders and directors)	48	9,628	48	9,628
Total trade receivables - related parties	48	9,628	48	9,628

(Unaudited but reviewed)

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	30 April	31 July	30 April	31 July
	2023	2022	2023	2022
<b><u>Doctor fee payable - related persons</u></b>				
Related persons (directors and management)	693	929	693	929
Total doctor fee payable - related persons	693	929	693	929

### **Directors and management's benefits**

During the three-month and nine-month periods ended 30 April 2023 and 2022, the Company had employee benefit expenses to its directors and management as below.

(Unit: Thousand Baht)

	Consolidated and separate financial statements			
	For three-month periods		For nine-month periods	
	ended 30 April		ended 30 April	
	2023	2022	2023	2022
Short-term employee benefits	12,771	12,406	36,440	39,886
Post-employment benefits	626	1,535	1,887	4,559
Total	13,397	13,941	38,327	44,445

### **3. Cash and cash equivalents**

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	30 April	31 July	30 April	31 July
	2023	2022	2023	2022
Cash	8,389	8,218	8,389	8,218
Bank deposits	1,121,989	691,350	1,120,154	688,801
Total cash and cash equivalents	1,130,378	699,568	1,128,543	697,019

As at 30 April 2023, bank deposits in savings accounts carried interests between 0.15 and 1.50 percent per annum (31 July 2022: between 0.05 and 0.50 percent per annum).

**4. Trade and other receivables**

	(Unit: Thousand Baht)			
	Consolidated financial statements		Separate financial statements	
	30 April 2023	31 July 2022	30 April 2023	31 July 2022
<b><u>Trade receivables - related parties</u></b>				
Aged on the basis of due dates				
Past due				
Up to 3 months	-	2,787	-	2,787
3 - 6 months	-	6,788	-	6,788
6 - 12 months	14	53	14	53
Over 12 months	34	-	34	-
Total trade receivables - related parties	48	9,628	48	9,628
<b><u>Trade receivables - unrelated parties</u></b>				
Aged on the basis of due dates				
Not yet due	84,632	88,947	84,632	88,947
Past due				
Up to 3 months	80,097	94,342	80,097	94,342
3 - 6 months	11,302	46,035	11,302	46,035
6 - 12 months	11,927	124,724	11,927	124,724
Over 12 months	46,034	4,252	46,034	4,252
Total trade receivables - unrelated parties	233,992	358,300	233,992	358,300
Less: Allowance for expected credit losses	(28,029)	(15,360)	(28,029)	(15,360)
Total trade receivables - unrelated parties - net	205,963	342,940	205,963	342,940
Total trade receivables - net	206,011	352,568	206,011	352,568
<b><u>Other receivables</u></b>				
Other receivables - unrelated parties	8,543	7,084	8,362	6,904
Accrued interest income	1,654	1,116	1,654	1,116
Total other receivables	10,197	8,200	10,016	8,020
Total trade and other receivables - net	216,208	360,768	216,027	360,588

**5. Other current financial assets**

As at 30 April 2023 and 31 July 2022, other current financial assets consisted of the following:

(Unit: Thousand Baht)

	Consolidated and separate financial statements			
	Other current financial assets		Interest rate (percent per annum)	
	30 April 2023	31 July 2022	30 April 2023	31 July 2022
Fixed deposits at financial institutions (6 - 12 months)	170,495	472,547	0.50 - 2.00	0.15 - 1.15
Total other current financial assets	170,495	472,547		

**6. Investment in subsidiary**

Details of investments in subsidiary as presented in the separate financial statements are as follows:

(Unit: Thousand Baht)

Company's name	Type of relation	Shareholding percentage		Cost	
		30 April 2023	31 July 2022	30 April 2023	31 July 2022
		(%)	(%)		
<b>Local subsidiary</b>					
Jatu Charoen Development Company Limited	Direct holding	99.97	99.97	1,000	1,000

On 13 December 2021, the Board of Directors' meeting No. 5/2021 resolved to approve the establishment of a new subsidiary, Jatu Charoen Development Company Limited, which is engaged in health establishment and hotel business, providing elderly and dependency care both onsite and offsite as well as distributions of medicines, supplement products, medical supplies and equipments. The subsidiary has a registered capital of 10,000 shares with a par value of Baht 100 per share, totaling Baht 1 million. The subsidiary registered the establishment with the Department of Business Development, the Ministry of Commerce on 18 February 2022.

**7. Property, plant and equipment**

Movements in the property, plant and equipment account during the nine-month period ended 30 April 2023 are summarised below.

	(Unit: Thousand Baht)
	Consolidated and separate financial statements
	<u>                    </u>
Net book value as at 1 August 2022	778,999
Additions during the period - at cost	193,320
Disposals during the period - net book value at disposal date	(1,082)
Depreciation for the period	<u>(68,531)</u>
Net book value as at 30 April 2023	<u>902,706</u>

**8. Right-of-use assets**

Movements in the Right-of-use assets account during the nine-month period ended 30 April 2023 are summarised below.

	(Unit: Thousand Baht)
	Consolidated and separate financial statements
	<u>                    </u>
Net book value as at 1 August 2022	592,180
Amortisation for the period	<u>(16,846)</u>
Net book value as at 30 April 2023	<u>575,334</u>

The Company entered into a long-term lease agreement for lease of land and building which are the current operation hospital building with Thai Red Cross Society. The agreement is for a period of 30 years, from 9 November 2018 to 8 November 2048 with the lease payment of Baht 668 million, being payable in full upon signing the new lease agreement. The Company paid the lease payment of Baht 668 million to the Thai Red Cross Society on 22 February 2019.

(Unaudited but reviewed)

## 9. Trade and other payables

(Unit: Thousand Baht)

	Consolidated		Separate	
	financial statements		financial statements	
	30 April	31 July	30 April	31 July
	2023	2022	2023	2022
Trade payables - unrelated parties	92,687	93,143	92,677	92,383
Other payables - unrelated parties	21,140	23,828	21,140	23,828
Accounts payable - construction and equipment purchases	45,934	49,313	45,934	49,313
Accrued expenses	38,896	43,964	38,708	43,608
Total trade and other payables	<u>198,657</u>	<u>210,248</u>	<u>198,459</u>	<u>209,132</u>

## 10. Income tax

Interim corporate income tax is calculated on profit before income tax for the period, using the estimated effective tax rate for the year.

Income tax expenses for the three-month and nine-month periods ended 30 April 2023 and 2022 are made up follows:

(Unit: Thousand Baht)

	For three-month periods ended 30 April			
	Consolidated		Separate	
	financial statements		financial statements	
	2023	2022	2023	2022
<b>Current income tax:</b>				
Interim corporate income tax charge	17,716	27,485	17,715	27,390
<b>Deferred tax:</b>				
Relating to origination and reversal of temporary differences	519	(373)	519	(373)
<b>Income tax expenses reported in the statements of comprehensive income</b>	<u>18,235</u>	<u>27,112</u>	<u>18,234</u>	<u>27,017</u>

(Unaudited but reviewed)

(Unit: Thousand Baht)

For nine-month periods ended 30 April

	Consolidated		Separate	
	financial statements	financial statements	financial statements	financial statements
	<u>2023</u>	<u>2022</u>	<u>2023</u>	<u>2022</u>
<b>Current income tax:</b>				
Interim corporate income tax charge	59,142	92,128	59,133	92,033
<b>Deferred tax:</b>				
Relating to origination and reversal of temporary differences	<u>(3,204)</u>	<u>(2,342)</u>	<u>(3,204)</u>	<u>(2,342)</u>
<b>Income tax expenses reported in the statements of comprehensive income</b>	<u>55,938</u>	<u>89,786</u>	<u>55,929</u>	<u>89,691</u>

## 11. Dividends

<u>Dividends</u>	<u>Approved by</u>	<u>Total dividends</u> (Million Baht)	<u>Dividend per share</u> (Baht)
Final dividends for 2021	Annual General Meeting of the shareholders on 18 November 2021	<u>90.0</u>	0.50
Total dividends for 2022		<u>90.0</u>	
Final dividends for 2022	Annual General Meeting of the shareholders on 17 November 2022	<u>108.0</u>	0.60
Total dividends for 2023		<u>108.0</u>	

## 12. Operating segment information

Operating segment information is reported in a manner consistent with the internal reporting the chief operating decision maker has received and regularly reviewed to make decisions about resources to be allocated to the segment and assess its performance. The chief operating decision maker has been identified as Executive Committee.

The one main reportable operating segment of the Company is the hospital business and the single geographical area of its operation is Thailand. Segment performance is evaluated based on operating profit or loss and is measured consistently with operating profit or loss in the financial statements. As a result, all of the revenues, operating profits and assets as reflected in these financial statements pertain to the aforementioned reportable operating segment and geographical area.

### 13. Commitments and contingent liabilities

#### 13.1 Commitments under service agreements

The Company had total minimum payments to be paid in the future under the service agreements as follows:

	(Unit: Million Baht)	
	30 April 2023	31 July 2022
	<hr/>	<hr/>
Payable:		
In up to 1 year	14.2	10.0
In over 1 year and up to 3 years	1.4	2.6

#### 13.2 Capital commitments

As at 30 April 2023, the Company had capital commitments of Baht 36.6 million (31 July 2022: Baht 117.4 million) in respect of the acquisitions of buildings and building improvements, medical equipment and facility systems.

#### 13.3 Guarantees

- a. As at 30 April 2023, the Company had credit facilities with a commercial bank for overdrafts of Baht 20 million and short-term loans of Baht 10 million (31 July 2022: Credit facilities with a commercial bank for overdrafts of Baht 20 million and short-term loans of Baht 10 million).
- b. As at 30 April 2023, the Company had outstanding bank guarantees of approximately Baht 6.3 million issued by the bank on behalf of the Company in respect of electricity use as required in the normal course of business. (31 July 2022: Baht 4.8 million).

### 14. Approval of interim financial statements

These interim financial statements were authorised for issue by the Company's Board of Directors on 14 June 2023.